Mr. Nils Behrndt, Deputy Head of Unit, Directorate F2 (Pharmaceuticals), DG Enterprise and Industry, European Commission has agreed to join the TOPRA Advisory Council.
TOPRA received yet another endorsement of its leading role in the global regulatory affairs industry. Mr. Nils Behrndt, Deputy Head of Unit, Directorate F2 (Pharmaceuticals), DG Enterprise and Industry, European Commission has agreed to join the TOPRA Advisory Council.
Mr. Behrndt has enjoyed an illustrious career at the European Commission, previously serving as the Acting Head of the Directorate F2. Mr. Behrndt has served the Commission since 2000 as a lawyer and advisor. Previously, he served as a lawyer and researcher for a variety of organisations and entities within Germany. He holds law degrees from Germany and the United Kingdom as well as having a Ph.D. in public administration and law.
TOPRA's President, Margareth Jorvid said, "We are delighted that Nils has joined our ranks. TOPRA will benefit immensely from his guidance and technical expertise offered through our Advisory Council."
Ms. Jorvid went onto say, "I think that this appointment really shows the maturity of our organisation and our expanding appeal worldwide, but most especially within the European Union. We are proud to have such a high-ranking official from the European Commission join TOPRA's Advisory Council."
TOPRA members are currently drawn from 52 countries.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.